慢性炎性脱髓鞘性多发性神经根神经病（CIDP）是一种罕见的由免疫介导的脱髓鞘性周围神经病1。CIDP患者会经历一系列的行动和感觉问题，包括从坐姿站起来困难、疼痛和疲劳、经常绊倒或摔倒。随着疾病进展，许多患者需依赖轮椅且无法工作，对患者造成严重的疾病负 ...

A retrospective cohort study was done on 134,698 individuals enrolled in a US healthcare database from 1988 to 1995. The database consists of integrated pharmacy and medical claims from six ...

导读历经数十年的探索与发展，多发性硬化（MS）治疗已取得长足进步。早期启动高效疾病修饰治疗（DMT），实现无疾病活动证据（NEDA）是目前国内外指南一致推荐的MS治疗理念与目标。早期高效策略，是通往MS治愈之路的第一步。然而对于初始未接受高效治疗的M ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

Analyst Jonathan Chang from Leerink Partners reiterated a Buy rating on Zai Lab (ZLAB – Research Report) and keeping the price target at ...

导读多发性硬化（MS）是一种免疫介导的中枢神经系统炎性脱髓鞘疾病。近年来，随着国内外指南共识的更新，以及多种疾病修饰治疗（DMT）药物的研发和应用，MS的标准化诊疗水平得以显著提升。然而，我国MS管理仍面临着诊断延迟、DMT药物治疗率和规范化随访率低 ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...